By Katherine Hamilton
Carisma Therapeutics plans to explore strategic alternatives after cutting 95% of its workforce.
The Philadelphia biotechnology company said Monday its board of directors approved a revised operating plan. The plan is aimed at maximizing the value of its assets and of potential future royalty payments from an agreement with Moderna.
The board in March approved cutting 42 full-time employees, which represents 95% of its total workforce, Carisma said in a filing with the Securities and Exchange Commission. That came after the company cut 62 jobs in 2024.
Strategic alternatives could include selling or licensing its assets, or merging with another company, Carisma said.
Carisma estimates it has cash and cash equivalents sufficient to fund operations into the second half of 2025.
Shares fell 6% to a 52-week low of 31 cents after markets closed Monday.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 31, 2025 17:24 ET (21:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。